Viking Therapeutics
VKTX
432 hedge funds and large institutions have $2.95B invested in Viking Therapeutics in 2026 Q2 according to their latest regulatory filings, with 75 funds opening new positions, 143 increasing their positions, 131 reducing their positions, and 50 closing their positions.
210% more call options, than puts
Call options by funds: $358M | Put options by funds: $115M
50% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 50
21% more capital invested
Capital invested by funds: $2.43B → $2.95B (+$520M)
5% more funds holding
Funds holding: 413 → 432 (+19)
1.68% more ownership
Funds ownership: 63.45% → 65.13% (+1.7%)
9% more repeat investments, than reductions
Existing positions increased: 143 | Existing positions reduced: 131
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$39.1M |
| 2 |
JF
Jump Financial
Chicago,
Illinois
|
+$18.7M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$15.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.3M |
| 5 |
Morgan Stanley
New York
|
+$15.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Raymond James Financial
St Petersburg,
Florida
|
-$41.4M |
| 2 |
BlackRock
New York
|
-$22.3M |
| 3 |
Two Sigma Investments
New York
|
-$16M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$13.3M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$11.7M |
VKTX Hedge Fund Activity: Q2 2026 in Review
432 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q2 2026, worth a combined $2.95B — up 21% from $2.43B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new VKTX positions and 50 closed out — a net gain of 25 holders — while 143 added to existing stakes and 131 trimmed.
The largest buyer was State Street, adding an estimated $39.1M. The largest seller was Raymond James Financial, cutting an estimated $41.4M.
- 432 institutional investors held Viking Therapeutics (VKTX) as of Q2 2026, up from 413 in Q1 2026.
- Funds reported $2.95B of Viking Therapeutics stock for Q2 2026, up 21% quarter-over-quarter.
- 75 funds opened new Viking Therapeutics positions in Q2 2026 and 50 closed out, a net change of +25 holders.
- The largest Viking Therapeutics buyer in Q2 2026 was State Street, an estimated $39.1M added.
- The largest Viking Therapeutics seller in Q2 2026 was Raymond James Financial, an estimated $41.4M sold.
Based on aggregated 13F filings for Q2 2026.